• Je něco špatně v tomto záznamu ?

Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial

MR. Mehra, DL. Crandall, F. Gustafsson, UP. Jorde, JN. Katz, I. Netuka, N. Uriel, JM. Connors, P. Sood, G. Heatley, FD. Pagani

. 2021 ; 23 (7) : 1226-1237. [pub] 20210701

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025438
E-zdroje Online Plný text

NLK Medline Complete (EBSCOhost) od 2000-03-01 do Před 1 rokem
Wiley Free Content od 1999 do Před 1 rokem

Odkazy

PubMed 34142415
DOI 10.1002/ejhf.2275
Knihovny.cz E-zdroje

AIMS: Over decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous-flow pumps which have substantially improved long-term outcomes and quality of life. Contemporary LVAD therapy is beleaguered by haemocompatibility-related adverse events including thrombosis, stroke and bleeding. A fully magnetically levitated pump, the HeartMate 3 (HM3, Abbott, USA) LVAD, has been shown to be superior to the older HeartMate II (HMII, Abbott, USA) pump by improving haemocompatibility. Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a marked reduction in stroke rates, and only a modest decrease in bleeding complications. Since the advent of continuous-flow LVAD therapy, patients have been prescribed a combination of aspirin and anticoagulation therapy on the presumption that platelet activation and perturbations to the haemostatic axis determine their necessity. Observational studies in patients implanted with the HM3 LVAD who suffer bleeding have suggested a signal of reduced subsequent bleeding events with withdrawal of aspirin. The notion of whether antiplatelet therapy can be avoided in an effort to reduce bleeding complications has now been advanced. METHODS: To evaluate this hypothesis and its clinical benefits, the Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump (ARIES HM3) has been introduced as the first-ever international prospective, randomized, double-blind and placebo-controlled, non-inferiority trial in a patient population implanted with a LVAD. CONCLUSION: This paper reviews the biological and clinical role of aspirin (100 mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025438
003      
CZ-PrNML
005      
20211026133822.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ejhf.2275 $2 doi
035    __
$a (PubMed)34142415
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Mehra, Mandeep R $u Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
245    10
$a Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial / $c MR. Mehra, DL. Crandall, F. Gustafsson, UP. Jorde, JN. Katz, I. Netuka, N. Uriel, JM. Connors, P. Sood, G. Heatley, FD. Pagani
520    9_
$a AIMS: Over decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous-flow pumps which have substantially improved long-term outcomes and quality of life. Contemporary LVAD therapy is beleaguered by haemocompatibility-related adverse events including thrombosis, stroke and bleeding. A fully magnetically levitated pump, the HeartMate 3 (HM3, Abbott, USA) LVAD, has been shown to be superior to the older HeartMate II (HMII, Abbott, USA) pump by improving haemocompatibility. Experience with the HM3 LVAD suggests near elimination of de-novo pump thrombosis, a marked reduction in stroke rates, and only a modest decrease in bleeding complications. Since the advent of continuous-flow LVAD therapy, patients have been prescribed a combination of aspirin and anticoagulation therapy on the presumption that platelet activation and perturbations to the haemostatic axis determine their necessity. Observational studies in patients implanted with the HM3 LVAD who suffer bleeding have suggested a signal of reduced subsequent bleeding events with withdrawal of aspirin. The notion of whether antiplatelet therapy can be avoided in an effort to reduce bleeding complications has now been advanced. METHODS: To evaluate this hypothesis and its clinical benefits, the Antiplatelet Removal and Hemocompatibility Events with the HeartMate 3 Pump (ARIES HM3) has been introduced as the first-ever international prospective, randomized, double-blind and placebo-controlled, non-inferiority trial in a patient population implanted with a LVAD. CONCLUSION: This paper reviews the biological and clinical role of aspirin (100 mg) with LVADs and discusses the rationale and design of the ARIES HM3 trial.
650    _2
$a Aspirin $7 D001241
650    12
$a srdeční selhání $x terapie $7 D006333
650    12
$a podpůrné srdeční systémy $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kvalita života $7 D011788
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Crandall, Daniel L $u Clinical Affairs Heart Failure, Abbott, Chicago, IL, USA
700    1_
$a Gustafsson, Finn $u Cardiology, Rigshospitalet, Copenhagen, Denmark
700    1_
$a Jorde, Ulrich P $u Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Bronx, NY, USA
700    1_
$a Katz, Jason N $u Division of Cardiology, Duke University, Durham, NC, USA
700    1_
$a Netuka, Ivan $u Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic
700    1_
$a Uriel, Nir $u Heart Failure, Heart Transplant & Mechanical Circulatory Support, Columbia University Medical Center, New York, NY, USA
700    1_
$a Connors, Jean M $u Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA
700    1_
$a Sood, Poornima $u Clinical Affairs Heart Failure, Abbott, Chicago, IL, USA
700    1_
$a Heatley, Gerald $u Global Biometrics, Abbott, Chicago, IL, USA
700    1_
$a Pagani, Francis D $u Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA
773    0_
$w MED00006634 $t European journal of heart failure $x 1879-0844 $g Roč. 23, č. 7 (2021), s. 1226-1237
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34142415 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133828 $b ABA008
999    __
$a ok $b bmc $g 1714473 $s 1145945
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 7 $d 1226-1237 $e 20210701 $i 1879-0844 $m European journal of heart failure $n Eur J Heart Fail $x MED00006634
LZP    __
$a Pubmed-20211013
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace